A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor

Pedram Argani, Lei Zhang, Yun Shao Sung, Marissa J. White, Karin Miller, Mark Hopkins, Donald Small, Christine Pratilas, David Swanson, Brendan Dickson, Cristina R. Antonescu

Research output: Contribution to journalArticle

Abstract

We report an Xp11 translocation perivascular epithelioid cell tumor (PEComa) with a novel RBMX-TFE3 gene fusion, resulting from a paracentric X chromosome inversion, inv(X)(p11;q26). The neoplasm occurred in an otherwise healthy 12-year-old boy who presented with a large left renal mass with extension into the inferior vena cava. The patient was found to have multiple pulmonary metastases at diagnosis and died of disease 3 months later. The morphology (epithelioid clear cells with alveolar and nested architecture) and immunophenotype (TFE3 and HMB45 strongly positive; actin, desmin, and PAX8 negative) was typical of an Xp11 translocation PEComa; however, TFE3 rearrangement was initially not detected by routine TFE3 break-apart fluorescence in situ hybridization (FISH). Further RNA sequencing revealed a novel RBMX-TFE3 gene fusion, which was subsequently confirmed by fusion assay FISH, using custom design RBMX and TFE3 come-together probes. This report describes a novel TFE3 gene fusion partner, RBMX, in a pediatric renal PEComa patient associated with a fulminant clinical course. As documented in other intrachromosomal Xp11.2 inversions, such as fusions with NONO, RBM10, or GRIPAP1 genes, the TFE3 break-apart might be below the FISH resolution, resulting in a false negative result.

Original languageEnglish (US)
JournalGenes Chromosomes and Cancer
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Perivascular Epithelioid Cell Neoplasms
Gene Fusion
Fluorescence In Situ Hybridization
Pediatrics
Kidney
RNA Sequence Analysis
Epithelioid Cells
Desmin
Inferior Vena Cava
X Chromosome
Actins
Neoplasm Metastasis
Lung
Genes
Neoplasms

Keywords

  • renal neoplasm
  • TFE3
  • translocation

ASJC Scopus subject areas

  • Genetics
  • Cancer Research

Cite this

A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor. / Argani, Pedram; Zhang, Lei; Sung, Yun Shao; White, Marissa J.; Miller, Karin; Hopkins, Mark; Small, Donald; Pratilas, Christine; Swanson, David; Dickson, Brendan; Antonescu, Cristina R.

In: Genes Chromosomes and Cancer, 01.01.2019.

Research output: Contribution to journalArticle

Argani, Pedram ; Zhang, Lei ; Sung, Yun Shao ; White, Marissa J. ; Miller, Karin ; Hopkins, Mark ; Small, Donald ; Pratilas, Christine ; Swanson, David ; Dickson, Brendan ; Antonescu, Cristina R. / A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor. In: Genes Chromosomes and Cancer. 2019.
@article{41fdacceae9e4d97ab4559004b2a3fe6,
title = "A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor",
abstract = "We report an Xp11 translocation perivascular epithelioid cell tumor (PEComa) with a novel RBMX-TFE3 gene fusion, resulting from a paracentric X chromosome inversion, inv(X)(p11;q26). The neoplasm occurred in an otherwise healthy 12-year-old boy who presented with a large left renal mass with extension into the inferior vena cava. The patient was found to have multiple pulmonary metastases at diagnosis and died of disease 3 months later. The morphology (epithelioid clear cells with alveolar and nested architecture) and immunophenotype (TFE3 and HMB45 strongly positive; actin, desmin, and PAX8 negative) was typical of an Xp11 translocation PEComa; however, TFE3 rearrangement was initially not detected by routine TFE3 break-apart fluorescence in situ hybridization (FISH). Further RNA sequencing revealed a novel RBMX-TFE3 gene fusion, which was subsequently confirmed by fusion assay FISH, using custom design RBMX and TFE3 come-together probes. This report describes a novel TFE3 gene fusion partner, RBMX, in a pediatric renal PEComa patient associated with a fulminant clinical course. As documented in other intrachromosomal Xp11.2 inversions, such as fusions with NONO, RBM10, or GRIPAP1 genes, the TFE3 break-apart might be below the FISH resolution, resulting in a false negative result.",
keywords = "renal neoplasm, TFE3, translocation",
author = "Pedram Argani and Lei Zhang and Sung, {Yun Shao} and White, {Marissa J.} and Karin Miller and Mark Hopkins and Donald Small and Christine Pratilas and David Swanson and Brendan Dickson and Antonescu, {Cristina R.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/gcc.22801",
language = "English (US)",
journal = "Genes Chromosomes and Cancer",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - A novel RBMX-TFE3 gene fusion in a highly aggressive pediatric renal perivascular epithelioid cell tumor

AU - Argani, Pedram

AU - Zhang, Lei

AU - Sung, Yun Shao

AU - White, Marissa J.

AU - Miller, Karin

AU - Hopkins, Mark

AU - Small, Donald

AU - Pratilas, Christine

AU - Swanson, David

AU - Dickson, Brendan

AU - Antonescu, Cristina R.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We report an Xp11 translocation perivascular epithelioid cell tumor (PEComa) with a novel RBMX-TFE3 gene fusion, resulting from a paracentric X chromosome inversion, inv(X)(p11;q26). The neoplasm occurred in an otherwise healthy 12-year-old boy who presented with a large left renal mass with extension into the inferior vena cava. The patient was found to have multiple pulmonary metastases at diagnosis and died of disease 3 months later. The morphology (epithelioid clear cells with alveolar and nested architecture) and immunophenotype (TFE3 and HMB45 strongly positive; actin, desmin, and PAX8 negative) was typical of an Xp11 translocation PEComa; however, TFE3 rearrangement was initially not detected by routine TFE3 break-apart fluorescence in situ hybridization (FISH). Further RNA sequencing revealed a novel RBMX-TFE3 gene fusion, which was subsequently confirmed by fusion assay FISH, using custom design RBMX and TFE3 come-together probes. This report describes a novel TFE3 gene fusion partner, RBMX, in a pediatric renal PEComa patient associated with a fulminant clinical course. As documented in other intrachromosomal Xp11.2 inversions, such as fusions with NONO, RBM10, or GRIPAP1 genes, the TFE3 break-apart might be below the FISH resolution, resulting in a false negative result.

AB - We report an Xp11 translocation perivascular epithelioid cell tumor (PEComa) with a novel RBMX-TFE3 gene fusion, resulting from a paracentric X chromosome inversion, inv(X)(p11;q26). The neoplasm occurred in an otherwise healthy 12-year-old boy who presented with a large left renal mass with extension into the inferior vena cava. The patient was found to have multiple pulmonary metastases at diagnosis and died of disease 3 months later. The morphology (epithelioid clear cells with alveolar and nested architecture) and immunophenotype (TFE3 and HMB45 strongly positive; actin, desmin, and PAX8 negative) was typical of an Xp11 translocation PEComa; however, TFE3 rearrangement was initially not detected by routine TFE3 break-apart fluorescence in situ hybridization (FISH). Further RNA sequencing revealed a novel RBMX-TFE3 gene fusion, which was subsequently confirmed by fusion assay FISH, using custom design RBMX and TFE3 come-together probes. This report describes a novel TFE3 gene fusion partner, RBMX, in a pediatric renal PEComa patient associated with a fulminant clinical course. As documented in other intrachromosomal Xp11.2 inversions, such as fusions with NONO, RBM10, or GRIPAP1 genes, the TFE3 break-apart might be below the FISH resolution, resulting in a false negative result.

KW - renal neoplasm

KW - TFE3

KW - translocation

UR - http://www.scopus.com/inward/record.url?scp=85071846594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071846594&partnerID=8YFLogxK

U2 - 10.1002/gcc.22801

DO - 10.1002/gcc.22801

M3 - Article

C2 - 31408245

AN - SCOPUS:85071846594

JO - Genes Chromosomes and Cancer

JF - Genes Chromosomes and Cancer

SN - 1045-2257

ER -